vs
FEDERAL SIGNAL CORP（FSS）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是FEDERAL SIGNAL CORP的1.8倍（$1.0B vs $597.1M），豪洛捷净利率更高（17.1% vs 10.2%，领先6.9%），FEDERAL SIGNAL CORP同比增速更快（26.5% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $89.5M），过去两年FEDERAL SIGNAL CORP的营收复合增速更高（18.5% vs 1.5%）
联邦信号公司是20世纪早期的美国企业，主营铁路信号设备的制造业务，总部坐落于美国纽约州奥尔巴尼市，其生产的相关信号产品在当时的美国轨道交通行业得到了广泛应用，具备一定的行业知名度。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
FSS vs HOLX — 直观对比
营收规模更大
HOLX
是对方的1.8倍
$597.1M
营收增速更快
FSS
高出24.0%
2.5%
净利率更高
HOLX
高出6.9%
10.2%
自由现金流更多
HOLX
多$125.7M
$89.5M
两年增速更快
FSS
近两年复合增速
1.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $597.1M | $1.0B |
| 净利润 | $60.8M | $179.1M |
| 毛利率 | 28.4% | 56.0% |
| 营业利润率 | 14.0% | 22.6% |
| 净利率 | 10.2% | 17.1% |
| 营收同比 | 26.5% | 2.5% |
| 净利润同比 | 21.6% | -10.9% |
| 每股收益（稀释后） | $0.99 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSSHOLX
| Q4 25 | $597.1M | $1.0B | ||
| Q3 25 | $555.0M | $1.0B | ||
| Q2 25 | $564.6M | $1.0B | ||
| Q1 25 | $463.8M | $1.0B | ||
| Q4 24 | $472.0M | $1.0B | ||
| Q3 24 | $474.2M | $988.0M | ||
| Q2 24 | $490.4M | $1.0B | ||
| Q1 24 | $424.9M | $1.0B |
净利润FSSHOLX
| Q4 25 | $60.8M | $179.1M | ||
| Q3 25 | $68.1M | $187.2M | ||
| Q2 25 | $71.4M | $194.9M | ||
| Q1 25 | $46.3M | $-17.4M | ||
| Q4 24 | $50.0M | $201.0M | ||
| Q3 24 | $53.9M | $178.6M | ||
| Q2 24 | $60.8M | $194.5M | ||
| Q1 24 | $51.6M | $169.9M |
毛利率FSSHOLX
| Q4 25 | 28.4% | 56.0% | ||
| Q3 25 | 29.1% | 55.6% | ||
| Q2 25 | 30.0% | 56.3% | ||
| Q1 25 | 28.2% | 37.5% | ||
| Q4 24 | 28.1% | 56.8% | ||
| Q3 24 | 29.6% | 56.4% | ||
| Q2 24 | 29.4% | 55.4% | ||
| Q1 24 | 27.3% | 53.3% |
营业利润率FSSHOLX
| Q4 25 | 14.0% | 22.6% | ||
| Q3 25 | 16.9% | 22.6% | ||
| Q2 25 | 17.3% | 24.9% | ||
| Q1 25 | 14.2% | -0.7% | ||
| Q4 24 | 14.9% | 22.5% | ||
| Q3 24 | 16.0% | 23.3% | ||
| Q2 24 | 16.5% | 24.1% | ||
| Q1 24 | 12.8% | 20.7% |
净利率FSSHOLX
| Q4 25 | 10.2% | 17.1% | ||
| Q3 25 | 12.3% | 17.8% | ||
| Q2 25 | 12.6% | 19.0% | ||
| Q1 25 | 10.0% | -1.7% | ||
| Q4 24 | 10.6% | 19.7% | ||
| Q3 24 | 11.4% | 18.1% | ||
| Q2 24 | 12.4% | 19.2% | ||
| Q1 24 | 12.1% | 16.7% |
每股收益（稀释后）FSSHOLX
| Q4 25 | $0.99 | $0.79 | ||
| Q3 25 | $1.11 | $0.84 | ||
| Q2 25 | $1.16 | $0.86 | ||
| Q1 25 | $0.75 | $-0.08 | ||
| Q4 24 | $0.80 | $0.87 | ||
| Q3 24 | $0.87 | $0.75 | ||
| Q2 24 | $0.99 | $0.82 | ||
| Q1 24 | $0.84 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.7M | $2.4B |
| 总债务越低越好 | $564.6M | $2.5B |
| 股东权益账面价值 | $1.4B | $5.2B |
| 总资产 | $2.4B | $9.2B |
| 负债/权益比越低杠杆越低 | 0.41× | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资FSSHOLX
| Q4 25 | $63.7M | $2.4B | ||
| Q3 25 | $54.4M | $2.2B | ||
| Q2 25 | $64.7M | $1.9B | ||
| Q1 25 | $57.5M | $1.6B | ||
| Q4 24 | $91.1M | $2.0B | ||
| Q3 24 | $73.7M | $2.3B | ||
| Q2 24 | $48.6M | $2.4B | ||
| Q1 24 | $48.9M | $2.2B |
总债务FSSHOLX
| Q4 25 | $564.6M | $2.5B | ||
| Q3 25 | $201.2M | $2.5B | ||
| Q2 25 | $258.3M | $2.5B | ||
| Q1 25 | $266.9M | $2.5B | ||
| Q4 24 | $204.4M | $2.5B | ||
| Q3 24 | $223.3M | $2.5B | ||
| Q2 24 | $248.8M | $2.5B | ||
| Q1 24 | $266.8M | $2.6B |
股东权益FSSHOLX
| Q4 25 | $1.4B | $5.2B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.3B | $4.8B | ||
| Q1 25 | $1.2B | $4.6B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | $1.1B | $5.1B | ||
| Q2 24 | $1.1B | $5.0B | ||
| Q1 24 | $1.0B | $4.8B |
总资产FSSHOLX
| Q4 25 | $2.4B | $9.2B | ||
| Q3 25 | $1.9B | $9.0B | ||
| Q2 25 | $1.9B | $8.8B | ||
| Q1 25 | $1.9B | $8.5B | ||
| Q4 24 | $1.8B | $8.7B | ||
| Q3 24 | $1.7B | $9.2B | ||
| Q2 24 | $1.7B | $8.9B | ||
| Q1 24 | $1.7B | $8.7B |
负债/权益比FSSHOLX
| Q4 25 | 0.41× | 0.48× | ||
| Q3 25 | 0.15× | 0.50× | ||
| Q2 25 | 0.20× | 0.52× | ||
| Q1 25 | 0.22× | 0.55× | ||
| Q4 24 | 0.17× | 0.53× | ||
| Q3 24 | 0.19× | 0.49× | ||
| Q2 24 | 0.23× | 0.51× | ||
| Q1 24 | 0.26× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.2M | $229.9M |
| 自由现金流经营现金流 - 资本支出 | $89.5M | $215.2M |
| 自由现金流率自由现金流/营收 | 15.0% | 20.5% |
| 资本支出强度资本支出/营收 | 1.3% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.60× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $227.1M | $1.0B |
8季度趋势，按日历期对齐
经营现金流FSSHOLX
| Q4 25 | $97.2M | $229.9M | ||
| Q3 25 | $61.1M | $355.1M | ||
| Q2 25 | $59.7M | $343.3M | ||
| Q1 25 | $36.7M | $169.4M | ||
| Q4 24 | $90.6M | $189.3M | ||
| Q3 24 | $68.8M | $367.0M | ||
| Q2 24 | $40.6M | $405.8M | ||
| Q1 24 | $31.3M | $292.4M |
自由现金流FSSHOLX
| Q4 25 | $89.5M | $215.2M | ||
| Q3 25 | $54.1M | $341.4M | ||
| Q2 25 | $52.4M | $330.5M | ||
| Q1 25 | $31.1M | $153.9M | ||
| Q4 24 | $82.1M | $172.5M | ||
| Q3 24 | $60.9M | $350.6M | ||
| Q2 24 | $24.8M | $385.3M | ||
| Q1 24 | $22.9M | $279.6M |
自由现金流率FSSHOLX
| Q4 25 | 15.0% | 20.5% | ||
| Q3 25 | 9.7% | 32.5% | ||
| Q2 25 | 9.3% | 32.3% | ||
| Q1 25 | 6.7% | 15.3% | ||
| Q4 24 | 17.4% | 16.9% | ||
| Q3 24 | 12.8% | 35.5% | ||
| Q2 24 | 5.1% | 38.1% | ||
| Q1 24 | 5.4% | 27.5% |
资本支出强度FSSHOLX
| Q4 25 | 1.3% | 1.4% | ||
| Q3 25 | 1.3% | 1.3% | ||
| Q2 25 | 1.3% | 1.3% | ||
| Q1 25 | 1.2% | 1.5% | ||
| Q4 24 | 1.8% | 1.6% | ||
| Q3 24 | 1.7% | 1.7% | ||
| Q2 24 | 3.2% | 2.0% | ||
| Q1 24 | 2.0% | 1.3% |
现金转化率FSSHOLX
| Q4 25 | 1.60× | 1.28× | ||
| Q3 25 | 0.90× | 1.90× | ||
| Q2 25 | 0.84× | 1.76× | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 1.81× | 0.94× | ||
| Q3 24 | 1.28× | 2.05× | ||
| Q2 24 | 0.67× | 2.09× | ||
| Q1 24 | 0.61× | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSS
| Vehiclesandequipment | $403.4M | 68% |
| Parts | $66.8M | 11% |
| Publicsafetyandsecurityequipment | $62.2M | 10% |
| Rentalincome | $19.0M | 3% |
| Industrialsignalingequipment | $18.2M | 3% |
| Other | $14.9M | 2% |
| Warningsystems | $12.6M | 2% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
